ClinicalTrials.gg
CompletedNCT05590585DISCOVERUpdated May 27, 2026Results posted

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

A Phase 4 interventional study of dupilumab and Topical emollient (moisturizer) in Moderate-to-Severe Atopic Dermatitis and Atopic Eczema, sponsored by Regeneron Pharmaceuticals. Completed at 30 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
23rd of 50
124 · median 75
Started
2023
with 6 others
Phase 4
24 of 50
4 open now
Registered
40th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 23rd largest by enrollment, is one of 7 that started in 2023, is one of 24 in phase 4, and was the 40th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.

From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis.

The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in your blood at different times
  • How much the study drug improves quality of life and mental health
03

Conditions studied

  • Moderate-to-Severe Atopic Dermatitis
  • Atopic Eczema

Keywords

  • Eczematous Lesions
  • Pruritus
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Skin of color, defined as Fitzpatrick skin type ≥4 at screening visit
  2. Diagnosis of moderate-to-severe atopic dermatitis (AD) that cannot be adequately controlled with topical AD medications, as defined in protocol
  3. Has applied a stable dose of topical emollient (moisturizer) twice daily as per physician recommendation starting at screening visit

Key Exclusion Criteria:

  1. Self-reported Caucasian or White race
  2. Adolescent body weight less than 30 kg at screening
  3. Prior use of dupilumab within 6 months of screening
  4. Concomitant skin diseases or other pigmentary disorder that could confound AD assessments
  5. Current or prior use, within 12 weeks before the screening visit, of phototherapy or tanning beds
  6. Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline
  7. Treatment with topical (TCS) or topical calcineurin inhibitors (TCI) within 7 days prior to baseline
  8. Planned or anticipated use of any prohibited medications and procedures, as defined in protocol
  9. Has received a COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study drug

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    dupilumab

    Adolescents and adults will receive 1 of 2 dose regimens based on age and body weight

    Drug: dupilumab · Other: Topical emollient (moisturizer)

Interventions

  • Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose

    Also known as: Dupixent®, R668, SAR231893

  • OtherTopical emollient (moisturizer)

    Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 24.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With an Investigator's Global Assessment (IGA) Score 0 to 1

    IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Percentage of participants with IGA "0" or "1" are reported at each visit.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  2. Percent Change From Baseline in EASI Score

    The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  3. Change From Baseline in EASI Score

    The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  4. Percentage of Participants With ≥50% Reduction From Baseline in EASI Score (EASI-50)

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to the given time point.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  5. Percentage of Participants With ≥75% Reduction From Baseline in EASI Score (EASI-75)

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to the given time point.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  6. Percentage of Participants With ≥90% Reduction From Baseline in EASI Score (EASI-90)

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-90 responders were the participants who achieved ≥90% overall improvement in EASI score from baseline to the given time point.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  7. Percent Change From Baseline in Total Scoring Atopic Dermatitis (SCORAD) Score

    The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  8. Percentage of Participants With ≥50% Reduction From Baseline in SCORAD Score (SCORAD-50)

    SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). A decrease in score indicated improvement. SCORAD-50 was defined as ≥50% reduction from baseline in SCORAD score.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  9. Percentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily Peak Pruritus (PP) Numerical Rating Scale (NRS) Score ≥3

    Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  10. Percentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily PP NRS Score ≥4

    Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  11. Percent Change From Baseline in Weekly Average of Daily PP NRS Score

    Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  12. Change From Baseline in Weekly Average of Daily PP NRS Score

    Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  13. Percent Change From Baseline in Percent Body Surface Area (BSA)

    BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region was: head and neck \[9%\], interior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). BSA was reported as a percentage of all major body sections combined.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  14. Change From Baseline in Health-related Quality of Life (QOL) as Measured by Dermatology Life Quality Index (DLQI; Age ≥16) Score

    DLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on QOL; over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL). A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  15. Change From Baseline in Health-related QOL as Measured by Children's Dermatology Life Quality Index (CDLQI; Age <16) Score

    CDLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on quality of life (QOL); over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL) in children. A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  16. Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score

    POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (Higher score indicative of more severe symptoms). Total score was an average of the disease symptoms assessed. A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  17. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score

    The Hospital Anxiety and Depression Scale (HADS) is a screening tool designed to assess anxiety and depression. The scale consists of 14 items, divided into two subscales: Anxiety (HADS-A): 7 items; Depression (HADS-D): 7 items. The range of the total score is 0-42 (sum of HADS-A and HADS-D), with higher score indicating more severe overall psychological distress. The two subscales can be reported separately, each with a score range of 0-21, with higher score indicating more severe symptoms of anxiety or depression. A decrease in either the total score or a subscale score indicates improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  18. Change From Baseline in Skin Pain NRS (SP NRS) Score

    SP NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants selected the number between 0 and 10 that fit best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain imaginable). A decrease in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  19. Change From Baseline in Weekly Average Sleep Quality NRS Score

    Sleep Quality NRS is an 11-point scale (0 to 10) in which 0 indicated worst possible sleep while 10 indicated best possible sleep. An increase in score indicated improvement.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  20. Percentage of Participants With Patient Global Impression of Disease (PGID) Response as No Symptoms

    PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" at the specified timepoints.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  21. Percentage of Participants With PGID Response as No Symptoms or Mild Symptoms

    PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" or "Mild symptoms" at the specified timepoints.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  22. Percentage of Participants Who Rated Their Eczema Symptoms in the Patient Global Impression of Change (PGIC) as "Much Better"

    The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Much better" at the specified timepoints.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  23. Percentage of Participants Who Rated Their Eczema Symptoms in the PGIC as "Moderately Better"

    The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Moderately better" at the specified timepoints.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24

  24. Number of Participants With Non-herpetic Skin Infection Treatment-emergent Adverse Events (TEAEs)

    A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Data are reported for the number of participants with non-herpetic skin infection TEAEs. A summary of all serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Day 1 through Week 24

  25. Change From Baseline in Total Immunoglobulin (E) IgE

    Serum samples were collected to measure concentrations of IgE.

    Time frame: Weeks 4, 12 and 24

  26. Percent Change From Baseline in Total IgE

    Serum samples were collected to measure concentrations of IgE.

    Time frame: Weeks 4, 12 and 24

  27. Trough Concentration of Functional Dupilumab in Serum

    Adolescents and adults received 1 of 2 dose regimens based on age and body weight. The trough concentration of functional dupilumab in serum for the 2 dose regimens at the specified time points are presented. Participants treated and had at least one evaluable post-first-dose concentration measurement.

    Time frame: Week 12 and Week 24

07

Results

Posted Jan 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneDupilumab
Started124
Received at least 1 dose of dupilumab124
Completed120
Not completed4
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject1

Outcome measures

SecondaryPercentage of Participants With an Investigator's Global Assessment (IGA) Score 0 to 1

IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Percentage of participants with IGA "0" or "1" are reported at each visit.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Score 0 to 1
percentage of participantsDupilumab
Week 20.9
Week 46.8
Week 815.9
Week 1225.9
Week 1635.2
Week 2045.4
Week 2444.0
SecondaryPercent Change From Baseline in EASI Score

The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · percent change
Percent Change From Baseline in EASI Score
percent changeDupilumab
Week 2-25.929 ± 29.782
Week 4-46.092 ± 30.000
Week 8-67.270 ± 25.689
Week 12-70.999 ± 25.798
Week 16-73.276 ± 32.975
Week 20-79.185 ± 23.612
Week 24-79.941 ± 25.634
SecondaryChange From Baseline in EASI Score

The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on scale
Change From Baseline in EASI Score
score on scaleDupilumab
Week 2-7.105 ± 7.504
Week 4-12.097 ± 9.338
Week 8-17.779 ± 10.178
Week 12-18.475 ± 9.768
Week 16-19.460 ± 11.663
Week 20-20.985 ± 11.249
Week 24-20.980 ± 11.071
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in EASI Score (EASI-50)

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to the given time point.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in EASI Score (EASI-50)
percentage of participantsDupilumab
Week 217.2
Week 447.9
Week 877.9
Week 1284.3
Week 1684.3
Week 2089.7
Week 2489.0
SecondaryPercentage of Participants With ≥75% Reduction From Baseline in EASI Score (EASI-75)

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to the given time point.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥75% Reduction From Baseline in EASI Score (EASI-75)
percentage of participantsDupilumab
Week 23.4
Week 423.1
Week 850.4
Week 1256.5
Week 1663.9
Week 2074.2
Week 2476.0
SecondaryPercentage of Participants With ≥90% Reduction From Baseline in EASI Score (EASI-90)

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-90 responders were the participants who achieved ≥90% overall improvement in EASI score from baseline to the given time point.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥90% Reduction From Baseline in EASI Score (EASI-90)
percentage of participantsDupilumab
Week 20.9
Week 45.1
Week 815.0
Week 1227.8
Week 1638.9
Week 2041.2
Week 2442.0
SecondaryPercent Change From Baseline in Total Scoring Atopic Dermatitis (SCORAD) Score

The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · percent change
Percent Change From Baseline in Total Scoring Atopic Dermatitis (SCORAD) Score
percent changeDupilumab
Week 2-18.5 ± 17.8
Week 4-30.2 ± 22.6
Week 8-44.4 ± 22.8
Week 12-50.5 ± 23.0
Week 16-53.2 ± 26.0
Week 20-55.6 ± 24.3
Week 24-59.3 ± 26.0
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in SCORAD Score (SCORAD-50)

SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). A decrease in score indicated improvement. SCORAD-50 was defined as ≥50% reduction from baseline in SCORAD score.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in SCORAD Score (SCORAD-50)
percentage of participantsDupilumab
Week 29.1
Week 416.2
Week 839.3
Week 1252.9
Week 1659.8
Week 2068.1
Week 2470.2
SecondaryPercentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily Peak Pruritus (PP) Numerical Rating Scale (NRS) Score ≥3

Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily Peak Pruritus (PP) Numerical Rating Scale (NRS) Score ≥3
percentage of participantsDupilumab
Week 214.3
Week 431.6
Week 848.2
Week 1254.6
Week 1664.8
Week 2068.0
Week 2465.6
SecondaryPercentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily PP NRS Score ≥4

Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily PP NRS Score ≥4
percentage of participantsDupilumab
Week 28.4
Week 419.7
Week 832.5
Week 1238.9
Week 1644.4
Week 2047.6
Week 2452.7
SecondaryPercent Change From Baseline in Weekly Average of Daily PP NRS Score

Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Weekly Average of Daily PP NRS Score
Percentage of changeDupilumab
Week 2-16.253 ± 25.364
Week 4-28.672 ± 28.427
Week 8-41.010 ± 33.346
Week 12-45.944 ± 31.358
Week 16-52.706 ± 30.812
Week 20-54.138 ± 28.698
Week 24-56.337 ± 31.036
SecondaryChange From Baseline in Weekly Average of Daily PP NRS Score

Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Weekly Average of Daily PP NRS Score
score on a scaleDupilumab
Week 2-1.234 ± 1.663
Week 4-2.058 ± 2.021
Week 8-2.939 ± 2.379
Week 12-3.237 ± 2.266
Week 16-3.741 ± 2.369
Week 20-3.823 ± 2.184
Week 24-3.981 ± 2.326
SecondaryPercent Change From Baseline in Percent Body Surface Area (BSA)

BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region was: head and neck \[9%\], interior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). BSA was reported as a percentage of all major body sections combined.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Percent Body Surface Area (BSA)
Percentage of changeDupilumab
Week 2-17.91 ± 24.92
Week 4-31.07 ± 31.06
Week 8-53.09 ± 30.67
Week 12-60.04 ± 31.45
Week 16-64.65 ± 32.79
Week 20-71.03 ± 28.50
Week 24-73.69 ± 28.31
SecondaryChange From Baseline in Health-related Quality of Life (QOL) as Measured by Dermatology Life Quality Index (DLQI; Age ≥16) Score

DLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on QOL; over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL). A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Health-related Quality of Life (QOL) as Measured by Dermatology Life Quality Index (DLQI; Age ≥16) Score
score on a scaleDupilumab
Week 2-4.5 ± 5.4
Week 4-5.6 ± 7.1
Week 8-6.7 ± 6.5
Week 12-7.6 ± 5.7
Week 16-7.6 ± 6.7
Week 20-8.5 ± 6.5
Week 24-8.3 ± 7.1
SecondaryChange From Baseline in Health-related QOL as Measured by Children's Dermatology Life Quality Index (CDLQI; Age <16) Score

CDLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on quality of life (QOL); over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL) in children. A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Health-related QOL as Measured by Children's Dermatology Life Quality Index (CDLQI; Age <16) Score
score on a scaleDupilumab
Week 2-4.2 ± 5.4
Week 4-5.0 ± 5.2
Week 8-5.1 ± 4.2
Week 12-6.3 ± 7.0
Week 16-8.5 ± 5.6
Week 20-8.6 ± 5.4
Week 24-7.8 ± 5.5
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) Total Score

POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (Higher score indicative of more severe symptoms). Total score was an average of the disease symptoms assessed. A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score
score on a scaleDupilumab
Week 2-5.6 ± 6.0
Week 4-8.3 ± 6.6
Week 8-10.3 ± 6.5
Week 12-11.0 ± 6.3
Week 16-11.2 ± 7.0
Week 20-11.3 ± 7.0
Week 24-11.5 ± 7.0
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score

The Hospital Anxiety and Depression Scale (HADS) is a screening tool designed to assess anxiety and depression. The scale consists of 14 items, divided into two subscales: Anxiety (HADS-A): 7 items; Depression (HADS-D): 7 items. The range of the total score is 0-42 (sum of HADS-A and HADS-D), with higher score indicating more severe overall psychological distress. The two subscales can be reported separately, each with a score range of 0-21, with higher score indicating more severe symptoms of anxiety or depression. A decrease in either the total score or a subscale score indicates improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score
score on a scaleDupilumab
Week 2-1.8 ± 5.0
Week 4-2.3 ± 5.5
Week 8-2.8 ± 5.6
Week 12-3.7 ± 5.5
Week 16-3.4 ± 5.8
Week 20-3.4 ± 6.1
Week 24-3.2 ± 6.3
SecondaryChange From Baseline in Skin Pain NRS (SP NRS) Score

SP NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants selected the number between 0 and 10 that fit best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain imaginable). A decrease in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Skin Pain NRS (SP NRS) Score
score on a scaleDupilumab
Week 2-2.3 ± 3.6
Week 4-2.6 ± 4.0
Week 8-3.2 ± 3.5
Week 12-3.3 ± 3.5
Week 16-3.0 ± 3.4
Week 20-3.0 ± 3.2
Week 24-2.9 ± 3.5
SecondaryChange From Baseline in Weekly Average Sleep Quality NRS Score

Sleep Quality NRS is an 11-point scale (0 to 10) in which 0 indicated worst possible sleep while 10 indicated best possible sleep. An increase in score indicated improvement.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Weekly Average Sleep Quality NRS Score
score on a scaleDupilumab
Week 20.473 ± 1.565
Week 40.910 ± 1.937
Week 81.204 ± 2.459
Week 121.281 ± 2.173
Week 161.239 ± 2.097
Week 201.045 ± 2.631
Week 241.210 ± 2.696
SecondaryPercentage of Participants With Patient Global Impression of Disease (PGID) Response as No Symptoms

PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" at the specified timepoints.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Global Impression of Disease (PGID) Response as No Symptoms
percentage of participantsDupilumab
Week 24.0
Week 44.0
Week 814.6
Week 1210.0
Week 1612.0
Week 2014.3
Week 2423.8
SecondaryPercentage of Participants With PGID Response as No Symptoms or Mild Symptoms

PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" or "Mild symptoms" at the specified timepoints.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With PGID Response as No Symptoms or Mild Symptoms
percentage of participantsDupilumab
Week 226.7
Week 446.0
Week 859.4
Week 1265.6
Week 1668.5
Week 2064.3
Week 2467.5
SecondaryPercentage of Participants Who Rated Their Eczema Symptoms in the Patient Global Impression of Change (PGIC) as "Much Better"

The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Much better" at the specified timepoints.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Rated Their Eczema Symptoms in the Patient Global Impression of Change (PGIC) as "Much Better"
percentage of participantsDupilumab
Week 215.8
Week 423.7
Week 844.1
Week 1245.6
Week 1650.5
Week 2055.2
Week 2453.8
SecondaryPercentage of Participants Who Rated Their Eczema Symptoms in the PGIC as "Moderately Better"

The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Moderately better" at the specified timepoints.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Rated Their Eczema Symptoms in the PGIC as "Moderately Better"
percentage of participantsDupilumab
Week 214.0
Week 427.2
Week 823.4
Week 1228.2
Week 1627.6
Week 2025.0
Week 2423.1
SecondaryNumber of Participants With Non-herpetic Skin Infection Treatment-emergent Adverse Events (TEAEs)

A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Data are reported for the number of participants with non-herpetic skin infection TEAEs. A summary of all serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Day 1 through Week 24
Reported as:
Count of participants · Participants
Number of Participants With Non-herpetic Skin Infection Treatment-emergent Adverse Events (TEAEs)
ParticipantsDupilumab
Number of Participants With Non-herpetic Skin Infection Treatment-emergent Adverse Events (TEAEs)1
SecondaryChange From Baseline in Total Immunoglobulin (E) IgE

Serum samples were collected to measure concentrations of IgE.

Time frame:
Weeks 4, 12 and 24
Reported as:
Mean · kU/L
Change From Baseline in Total Immunoglobulin (E) IgE
kU/LDupilumab
Week 4-493.277 ± 1964.991
Week 12-2284.021 ± 5579.402
Week 24-3177.471 ± 6959.014
SecondaryPercent Change From Baseline in Total IgE

Serum samples were collected to measure concentrations of IgE.

Time frame:
Weeks 4, 12 and 24
Reported as:
Mean · percent change
Percent Change From Baseline in Total IgE
percent changeDupilumab
Week 4-6.277 ± 62.301
Week 12-39.703 ± 25.145
Week 24-50.375 ± 69.291
SecondaryTrough Concentration of Functional Dupilumab in Serum

Adolescents and adults received 1 of 2 dose regimens based on age and body weight. The trough concentration of functional dupilumab in serum for the 2 dose regimens at the specified time points are presented. Participants treated and had at least one evaluable post-first-dose concentration measurement.

Time frame:
Week 12 and Week 24
Reported as:
Mean · mg/L
Trough Concentration of Functional Dupilumab in Serum
mg/LDupilumab
Dose Regimen 1: Week 1240.8 ± 28.7
Dose Regimen 2: Week 1243.9 ± 28.4
Dose Regimen 1: Week 2443.9 ± 28.0
Dose Regimen 2: Week 2449.6 ± 33.4
PrimaryPercentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)
percentage of participantsDupilumab
Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)76.0 (66.43 to 83.98)

Adverse events

Collected over Day 1 through Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab1/124 (0.8%)7/124 (5.6%)0/124 (0%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDupilumab
Septic shockInfections and infestations1/124
SinusitisInfections and infestations1/124
EncephalopathyNervous system disorders1/124
SeizureNervous system disorders1/124
IntussusceptionGastrointestinal disorders1/124
Bile duct stoneHepatobiliary disorders1/124
Drug hypersensitivityImmune system disorders1/124
ConcussionInjury, poisoning and procedural complications1/124
Blood pressure increasedInvestigations1/124
MyalgiaMusculoskeletal and connective tissue disorders1/124

Baseline characteristics

Full Analysis Set (FAS): All participants who were enrolled in the study and had at least 1 post-baseline efficacy assessment.

Age, Continuous
Age, Continuous(years)Dupilumab
Mean37.6 ± 16.9
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab
Female56
Male64
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dupilumab
Hispanic or Latino17
Not Hispanic or Latino100
Unknown or Not Reported3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dupilumab
Race — White3
Race — Black or African American98
Race — Asian13
Race — American Indian or Alaska Native3
Race — Native Hawaiian or Other Pacific Islander0
Race — Other3
08

Study locations

30 sites
  • Total Skin & Beauty Dermatology Center
    Birmingham, Alabama 35203, United States
  • The University Of Alabama At Birmingham
    Birmingham, Alabama 35233, United States
  • C2 Research Center, LLC
    Montgomery, Alabama 36117, United States
  • Center for Dermatology Clinical Research, inc.
    Fremont, California 94538, United States
  • UCSD/ Rady Children's Hospital
    San Diego, California 92123, United States
  • UCSF
    San Francisco, California 94118, United States
  • SF Research Institute
    San Francisco, California 94127, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Skin and Cancer Associates, LLP
    Miami, Florida 33137, United States
  • Century Research LLC
    Miami, Florida 33173, United States
  • Advanced Medical Research PC
    Atlanta, Georgia 30328, United States
  • Atlanta Biomedical Clinical Research LLC
    Atlanta, Georgia 30331, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Callender Dermatology and Cosmetic Center
    Glenn Dale, Maryland 20769, United States
  • Dermatology and Skin Cancer Specialists, LLC dba US Dermatology Partners
    Rockville, Maryland 20850, United States
  • Wayne State University Physician Group Dermatology
    Dearborn, Michigan 48126, United States
  • Revival Research Institute , LLC
    Troy, Michigan 48084, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Rao Dermatology
    Atlantic Highlands, New Jersey 07716, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • NYC Health + Hospital , Elmhurst Hospital Center
    Elmhurst, New York 11373, United States
  • Markowitz Medical
    New York, New York 10128, United States
  • Philip Fried, MD PLLC
    The Bronx, New York 10463, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • National Allergy and Asthma Research, LLC.
    North Charleston, South Carolina 29420, United States
  • Center for Clinical Studies, LTD.LLP
    Houston, Texas 77004, United States
  • Heights Dermatology & Aesthetic Center - Heights Location
    Houston, Texas 77008, United States
  • RFSA Dermatology
    San Antonio, Texas 78213, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Nov 2024, 22 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 21, 2022
StartActual
Jan 11, 2023
Primary completionActual
Nov 14, 2024
CompletionActual
Nov 14, 2024
Results first posted
Jan 2, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05590585
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Jan 11, 2023
Primary completion
Nov 14, 2024
Completion
Nov 14, 2024
Results posted
Jan 2, 2026
Last update
May 27, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion